论文部分内容阅读
前言自百日咳杆菌首次制成菌苗预防人类百日咳这一严重威胁婴幼儿生命的疾病以来,至今已有50多年的历史。目前世界各国大部地区仍在使用百日咳Ⅰ相菌制作的灭活全细胞菌苗。然而该菌苗对人体的毒性作用较重,异常反应的发生率较高,特别对极少数儿童可引起神经系统症状,甚至严重的脑损伤导致死亡,从而有的国家在全国范围内停用该菌苗,然而因停用反引起发病倍增,几年后又不得不恢复使用,但付作用的问题仍引人关注,许多国家都在努力研制付作用较小的组分菌苗。
Preface It is more than 50 years since Bordetella pertussis first produced a bacterin for the prevention of human whooping cough, a serious disease that threatens the lives of infants and young children. Currently in most parts of the world are still using the first phase of pertussis bacteria inactivated whole cell vaccine. However, the bacterin has a heavy toxicity on the human body and a high incidence of abnormal reaction, especially for a very small number of children, which can cause nervous system symptoms and even cause serious brain damage which leads to death in some countries in the whole country Vaccines, however, however, have had to be reintroduced several years later due to deactivation and anti-priming pathogenesis. However, the problem of pay-off remains a cause for concern and many countries are working hard on the development of smaller-component vaccinees.